NCT02852096Unknown不适用
Assessing Her2/Neu Expression in Gastric Cancer With Dual or Multiple Tumor Tissue Paraffin Blocks
Shanghai Zhongshan Hospital1 个研究点 分布在 1 个国家目标入组 600 人开始时间: 2015年11月1日最近更新:
适应症
干预措施
试验速览
- 阶段
- 不适用
- 发起方
- 入组人数
- 600
- 试验地点
- 1
- 主要终点
- The positive rate of cohort using dual or multiple tumor tissue paraffin blocks
研究概览
简要总结
One paraffin block is routinely used for Human Epidermal Growth Factor Receptor 2 (Her2/neu) immunohistochemistry (IHC) assessment. Here, investigators investigated if picking two or multiple paraffin blocks for Her2/neu evaluation is an economical, efficient and practical method, which may reduce false-negativity of Her2/neu IHC assessment due to intratumoral heterogeneity.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Diagnostic
- 盲法
- Single (Participant)
入排标准
- 年龄范围
- 18 Years 至 80 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Age between 18 to 80; Received curative surgery with primary gastric adenocarcinoma; Did not receive any preoperative treatment.
排除标准
- 未提供
研究组 & 干预措施
Dual or Multiple Paraffin Blocks
Experimental
Assessing Her2/neu Expression in Gastric Cancer with Dual or Multiple Tumor Tissue Paraffin Blocks
干预措施: Dual or Multiple Paraffin Blocks (Other)
One Paraffin Blocks
Active Comparator
Assessing Her2/neu Expression in Gastric Cancer with One Tumor Tissue Paraffin Blocks
干预措施: One Paraffin Blocks (Other)
结局指标
主要结局
The positive rate of cohort using dual or multiple tumor tissue paraffin blocks
时间窗: 24 months
次要结局
未报告次要终点
研究者
研究点 (1)
Loading locations...
相似试验
Unknown
不适用
The Clinical Study of Assessing HER-2 Expression in Gastric Cancer With Extra Tumor Tissue Paraffin Blocks Using ImmunohistochemistryGastric Cancer Surgical Specimens,18-80 Years Old, at Least Two Tumor Tissue BlocksNCT02843412Shanghai Zhongshan Hospital2,000
Unknown
1 期
Study of Ramucirumab, Trastuzumab and Paclitaxel in Patients With HER2-positive Recurrent/Metastatic Gastric Cancer (HER-RAM Study)Recurrent/Metastatic Gastric CancerNCT04888663Yonsei University50
已完成
不适用
Human Epidermal Growth Factor Receptor 2 (HER-2) Status in Gastric and Gastro-Esophageal Junction (GEJ) CarcinomaGastric Cancer, Gastroesophageal Junction CancerNCT02731313Hoffmann-La Roche420
已完成
不适用
Clinical usefulness of serum HER2 in gastric cancer (Serum Her2/neu elevation in gastric cancer; A Multicenter trial in Hokkaido)Gastric cancerJPRN-UMIN000009773First Department of Internal Medicine, Sapporo Medical University300
已完成
2 期
PF-00299804 Monotherapy in Patients With HER-2 Positive Advance Gastric CancerAdvanced Gastric CancerHER2NCT01152853Seoul National University Hospital28